Connection
Frank Scott to Antibodies, Monoclonal
This is a "connection" page, showing publications Frank Scott has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.539 |
|
|
|
-
Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis. 2013 Nov; 19(12):2625-33.
Score: 0.283
-
Haydek JP, Scott FI. Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence. Aliment Pharmacol Ther. 2021 09; 54(6):846-847.
Score: 0.122
-
Scott FI. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? Dig Dis Sci. 2020 08; 65(8):2158-2160.
Score: 0.113
-
Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in?Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016 07; 151(1):97-109.e4.
Score: 0.021